This company listing is no longer active
Cosmo Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Giovanni Di Napoli
Chief executive officer
€4.0m
Total compensation
| CEO salary percentage | 0.7% |
| CEO tenure | 1yr |
| CEO ownership | n/a |
| Management average tenure | 3.1yrs |
| Board average tenure | 1yr |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €4m | €27k | €133m |
Compensation vs Market: Giovanni's total compensation ($USD4.53M) is above average for companies of similar size in the German market ($USD1.28M).
Compensation vs Earnings: Insufficient data to compare Giovanni's compensation with company performance.
CEO
Giovanni Di Napoli (50 yo)
1yr
Tenure
€3,995,280
Compensation
Mr. Giovanni Di Napoli is Chief Executive Officer and Director of Cosmo Pharmaceuticals N.V. from May 24, 2024. He was President of Gastrointestinal at Medtronic plc. He is an accomplished leader with an e...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non Executive Chairman | 19.3yrs | €1.77m | no data | |
| CEO & Director | 1yr | €4.00m | no data | |
| Founder & Non-Executive Director | 19.3yrs | €2.64m | no data | |
| Executive VP of Corporate Governance | less than a year | €690.01k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 4.3yrs | no data | no data | |
| Qualified Person & Technical Director | 13.7yrs | no data | no data | |
| Chief Scientific Officer | 3.1yrs | no data | no data | |
| Chief Legal Counsel | less than a year | no data | no data | |
| Chief Manufacturing Officer | 28.3yrs | no data | no data | |
| President of Cosmo Intelligent Medical Devices | no data | no data | no data | |
| Chief AI Officer | 5.3yrs | no data | no data |
3.1yrs
Average Tenure
51yo
Average Age
Experienced Management: C43's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non Executive Chairman | 19.3yrs | €1.77m | no data | |
| CEO & Director | 1yr | €4.00m | no data | |
| Founder & Non-Executive Director | 19.3yrs | €2.64m | no data | |
| Executive VP of Corporate Governance | 1yr | €690.01k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 13.1yrs | €131.45k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 1yr | €131.58k | no data | |
| Non-Executive Director | 1yr | €131.58k | no data |
1.0yrs
Average Tenure
60.5yo
Average Age
Experienced Board: C43's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 02:06 |
| End of Day Share Price | 2025/04/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo Pharmaceuticals N.V. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |
| Laura Hindley | Berenberg |